Luci Berardi: Writing a New Chapter on Ovarian Cancer

April 15, 2021 10:30 am

Luci Berardi had known for three months that something was wrong. As a yoga practitioner and instructor, she was very much in tune with her body, and the changes she was noticing were odd and disconcerting.

First there was the … Read more

Cancer Discovery Could Revive Failed Treatments for Solid Tumors

April 5, 2021 11:00 am

New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.

The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more

What to Know About Telehealth for Ovarian Cancer

April 2, 2021 1:30 am

Ovarian cancer is a serious gynecologic cancer and the fifth leading cause of cancer-related deaths among women in the United States.1 To minimize the risk of the coronavirus disease (COVID-19) transmission while … Read more

Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer

March 26, 2021 1:00 pm

Ixabepilone plus bevacizumab yielded responses in a third of patients.

By Ian Ingram

Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.

Median progression-free … Read more

HIPEC Combo Doubles PFS in Advanced Ovarian Cancer

March 26, 2021 12:00 pm

Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.

By Charles Bankhead

Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.

Median progression-free survival (PFS) doubled … Read more

Kristen’s Story: Holding On to Hope

March 25, 2021 3:00 pm

October of 2019, I had my initial tumor removal via an oophorectomy. My oncologist was extremely empathetic and insisted that all measures would be taken to preserve my fertility given my age. However, on November 13, 2019, three weeks following … Read more

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

March 22, 2021 4:00 pm

By Chase Doyle

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more

PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status

March 22, 2021 3:00 pm

By Chase Doyle

Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more

Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer

March 21, 2021 5:00 pm

Responses in 37% of patients with AVB-500, higher without prior bevacizumab.

By Charles Bankhead

More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more

Recent Chemotherapy or Immunotherapy for Gynecologic Cancer Does Not Raise Risk of Death Due to COVID-19

March 21, 2021 4:00 pm

Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due … Read more

PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

March 20, 2021 4:00 pm

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.

By Charles Bankhead

A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.

Treatment with rucaparib (Rubraca) … Read more

High Tumor Mutational Burden Predicts Immunotherapy Response in Some—but Not All—Cancers

March 16, 2021 6:00 pm

High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.

The findings suggest that … Read more

Two Pathways, One Destination: Promising Drug Combination to Treat Ovarian Cancer

March 15, 2021 3:00 pm

By R. Colon-Thillet

Treatment for ovarian cancer across subtypes typically consists of platinum-based chemotherapies. However, this standard therapy is less effective against ovarian clear cell carcinoma (OCCC), a rare subtype of ovarian cancer with distinct pathology and genetic drivers. Advanced … Read more

Cancer Patients Shouldn’t Let Imaging Concerns Delay COVID-19 Vaccine

March 3, 2021 7:00 pm

By Lisa Rapaport

Patients with cancer shouldn’t delay COVID-19 vaccination despite the potential for clinically evident adenopathy on imaging done after vaccination, according to recommendations from a multidisciplinary panel of scientific experts.

Vaccination-associated adenopathy or axillary swelling may appear within … Read more

FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer

March 3, 2021 4:00 pm

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

By Courtney Marabella

The FDA has granted priority review to the new

Read more

Most Patients With Breast, Ovarian Cancer Patients Do Not Undergo Genetic Testing

March 1, 2021 7:00 pm

By Christina Bennett, MS

The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing.  Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more

REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer

February 25, 2021 5:00 pm

For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more

Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue

February 24, 2021 6:00 pm

An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

By Courtney Marabella… Read more

Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer

February 23, 2021 6:00 pm

By Matthew Stenger

In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more

Pap Test/Cervical Swab Samples Can Reveal Ovarian Cancer Biomarkers

February 22, 2021 10:00 am

 Sharon Worcester

Residual fixatives from liquid-based Pap tests and cervical swabs contain tumor-specific biomarkers for ovarian cancer, according to an analysis of proteins found in matched biospecimens from a woman with high grade serous ovarian cancer.

The findings suggest … Read more